Cardiovascular Systems, Inc. (NASDAQ:CSII) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07Submission of Matters to a Vote of Security Holders.
The Company held its 2018 Annual Meeting of Stockholders on November 14, 2018. Set forth below is a brief description of each matter voted upon at the meeting and the voting results with respect to each matter.
|
1. |
Proposal to elect Class I directors to hold office until the fiscal 2021 Annual Meeting of Stockholders: |
|
Class I Director’s Name |
For |
Against |
Abstain |
Broker Non-Votes |
|
Scott Bartos |
24,634,393 |
1,059,761 |
3,824,819 |
|
|
Edward Brown |
25,515,183 |
178,971 |
3,824,819 |
|
|
Augustine Lawlor |
24,435,494 |
1,258,660 |
3,824,819 |
|
2. |
Proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2019. |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
29,234,451 |
277,182 |
7,815 |
|
3. |
Proposal to cast a non-binding advisory vote on the compensation paid to the Company’s named executive officers. |
|
For |
Against |
Abstain |
Broker Non-Votes |
|
23,240,661 |
2,442,118 |
11,850 |
3,824,819 |
About Cardiovascular Systems, Inc. (NASDAQ:CSII)
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
